Rova-T was supposed to be the cancer drug that would bolster AbbVie’s revenues as revenues from the $20bn a year Humira (adalimumab) begin to dry up thanks to cheaper competitors. Bought into ...

Fears that Humira biosimilars will erode AbbVie's top line are overblown, an analyst said Monday as he reiterated his outperform rating on AbbVie stock. Please watch the video at Investors.com ...

However AbbVie’s Q3 results reveal the scale of the task ahead – Humira’s sales in the US continue to mount at nearly $4.8 billion, while Skyrizi and Rinvoq generated revenues of $379 ...

Humira sales in 2024 were $9 billion, down 58% from their peak. The good news is that AbbVie has already found a replacement for Humira with two blockbuster drugs: Skyrizi and Rinvoq. While these ...

This performance underscores AbbVie's ability to manage the transition away from Humira dependency successfully. InvestingPro analysis indicates net income is expected to grow this year ...

AbbVie’s former CEO Richard Gonzalez—who collected a $25.7 million payout for his final full year on the job in 2023—often ranked among the industry’s highest-paid CEOs during his tenure ...

AbbVie was downgraded to "Hold" due to high debt, fluctuating earnings, and declining Humira sales, but the stock outperformed with a 31% return since July 2024. Despite mixed quarterly results ...

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the ...